Identifying a Novel Role for Fractalkine (CX3CL1) in Memory CD8+ T Cell Accumulation in the Omentum of Obesity-Associated Cancer Patients

Immunological Functions of the Omentum

(2017) Selene Meza-Perez et al.   TRENDS IN IMMUNOLOGY

Brown adipose tissue in obesity: Fractalkine-receptor dependent immune cell recruitment affects metabolic-related gene expression

(2016) Ágnes Polyák et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis

(2016) Carmen Gerlach et al.   IMMUNITY

CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer

(2016) Melissa J Conroy et al.   IMMUNOLOGY AND CELL BIOLOGY

Parallel Profiles of Inflammatory and Effector Memory T Cells in Visceral Fat and Liver of Obesity-Associated Cancer Patients

(2016) Melissa J. Conroy et al.   INFLAMMATION

Functional classification of memory CD8+ T cells by CX3CR1 expression

(2015) Jan P. Böttcher et al.   Nature Communications

Fractalkine (CX3CL1) Is Involved in the Early Activation of Hypothalamic Inflammation in Experimental Obesity

(2014) Joseane Morari et al.   DIABETES

CX3CL1 (fractalkine) and its receptor CX3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin

(2014) Delphine Staumont-Sallé et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Circulating Fractalkine Levels Predict the Development of the Metabolic Syndrome

(2014) Yin Xueyao et al.   International Journal of Endocrinology

Establishing computed tomography–defined visceral fat area thresholds for use in obesity-related cancer research

(2013) Suzanne L. Doyle et al.   NUTRITION RESEARCH

Fractalkine mediates inflammatory pain through activation of satellite glial cells

(2013) G. R. Souza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic potential of the chemokine–receptor duo fractalkine/CX3CR1: an update

(2012) Jan G D'Haese et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

CX3CR1 Deficiency Does Not Influence Trafficking of Adipose Tissue Macrophages in Mice With Diet-Induced Obesity

(2012) David L. Morris et al.   Obesity

T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma

(2011) J. Lysaght et al.   BRITISH JOURNAL OF SURGERY

Fractalkine: A Cellular Link Between Adipose Tissue Inflammation and Vascular Pathologies

(2011) W. T. Cefalu   DIABETES

Fractalkine Is a Novel Human Adipochemokine Associated With Type 2 Diabetes

(2011) R. Shah et al.   DIABETES

CXCR3 in T cell function

(2011) Joanna R. Groom et al.   EXPERIMENTAL CELL RESEARCH

Upregulation of Fractalkine and Its Receptor, CX3CR1, is Associated With Coronary Plaque Rupture in Patients With Unstable Angina Pectoris

(2010) Hideyuki Ikejima et al.   CIRCULATION JOURNAL

Eotaxin-3/CC Chemokine Ligand 26 Is a Functional Ligand for CX3CR1

(2010) T. Nakayama et al.   JOURNAL OF IMMUNOLOGY

Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice

(2010) Amelia A. Staniland et al.   JOURNAL OF NEUROCHEMISTRY

CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung

(2010) Cyrille Mionnet et al.   NATURE MEDICINE

Chemokines and chemokine receptors: new insights into cancer-related inflammation

(2010) Gwendal Lazennec et al.   TRENDS IN MOLECULAR MEDICINE

An engineered CX3CR1 antagonist endowed with anti-inflammatory activity

(2009) Karim Dorgham et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

(2008) Andrew G Renehan et al.   LANCET

Chemokine receptor antagonists: overcoming developmental hurdles

(2008) Richard Horuk   NATURE REVIEWS DRUG DISCOVERY